OncoCyte a new buy at Lake Street on transplant rejection testing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 28 2025
0mins
Should l Buy ?
Source: SeekingAlpha
OncoCyte's Growth Potential: Lake Street Capital Markets has initiated coverage of OncoCyte with a buy rating, highlighting the company's opportunity for growth in transplant rejection testing using its VitaGraft Plus test, which aims to streamline testing processes for transplant centers.
Future Developments and Projections: The company plans to submit an application for FDA approval of VitaGraft Plus this year, with expectations for marketing by 2026, while targeting $20 million in recurring revenue from 20 transplant centers by 2025.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
